Champions Oncology, Inc. — Form 10-Q Summary
Business context and reporting period: The company provides oncology research services and technology for drug discovery and development, including pharmacology studies and its Lumin Bioinformatics platform. This report covers the fiscal second quarter and first six months ended October 31, 2022; comparisons are with the corresponding 2021 periods. Dollar amounts below are in millions unless stated otherwise.
Financial performance
| Metric | Three months ended Oct. 31, 2022 | Three months ended Oct. 31, 2021 | Six months ended Oct. 31, 2022 | Six months ended Oct. 31, 2021 |
|---|---|---|---|---|
| Revenue | $14.281 | $11.786 | $28.026 | $23.039 |
| Gross margin | 47.9% | 52.4% | 48.3% | 52.2% |
| Operating income (loss) | $0.007 | $0.263 | $(0.277) | $0.088 |
| Net income (loss) | $(0.016) | $0.277 | $(0.335) | $0.105 |
| Operating cash flow | Not presented separately | Not presented separately | $3.091 | $1.444 |
Revenue increased 21.2% for the quarter and 21.6% for the six-month period, primarily due to demand and larger in-vivo and ex-vivo pharmacology studies. Pharmacology services generated $13.480 million of quarterly revenue and $26.236 million over six months. Cost of oncology services grew faster than revenue, rising 32.7% for the quarter and 31.7% for six months; the company cited compensation, mice and supplies, and SaaS-related costs. Management attributed lower pharmacology margins to upfront study costs incurred before revenue recognition; increased Lumin depreciation and amortization also weighed on total margins.
Quarterly general and administrative expense increased 27.9% to $2.527 million; six-month expense rose 19.3% to $4.925 million, mainly due to compensation, IT, infrastructure growth, and higher bad-debt expense. Research and development increased 13.3% for the quarter and 19.3% for six months, reflecting investment in the therapeutic drug discovery platform.
Financial position and liquidity
- At October 31, 2022, cash was $10.826 million, versus $9.007 million at April 30, 2022. Six-month operating cash flow was $3.091 million; capital spending was $1.358 million; option exercises provided $0.086 million.
- Working capital was $1.9 million; current assets were $20.608 million and current liabilities were $18.736 million. Deferred revenue was $11.185 million.
- Total liabilities were $27.192 million and stockholders’ equity was $9.172 million. The filing reports no off-balance-sheet debt; operating lease liabilities totaled $8.965 million. The filing does not provide a separate total for other borrowings.
- Accumulated deficit was $72.317 million. Management expects positive operating cash flow for fiscal 2023 and believes cash and anticipated operating cash flow can fund operations for at least 12 months from filing. It cited potential cost reductions if revenue expectations are not met and cautioned that additional capital might not be available on acceptable terms.
Outlook, risks and other notable items
- No specific revenue, earnings, or other numerical guidance was provided. Management described ongoing investment in therapeutic discovery and a pipeline of targets at different discovery and validation stages; commercial strategy for resulting targets and therapeutics remains under development. Strategic options may include spin-outs or capital raises.
- Key risks include revenue expectations not materializing, execution of growth and platform investments, and the possibility that future capital could be unavailable on acceptable terms. Management refers investors to the risk factors in its fiscal 2022 Form 10-K.
- The company reported no current legal proceedings and no accrued liquidated damages under its registration-rights agreement, stating it anticipated continued compliance. Certain tumor-model licenses require royalties, including rates of 2%–20% under some agreements and possible annual minimums.
- Management concluded disclosure controls and procedures were effective as of October 31, 2022, with no material changes to internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether revenue growth continues and whether higher service costs and upfront study spending stabilize enough to recover gross margins.
- Whether management achieves its expectation of positive fiscal 2023 operating cash flow and maintains the stated liquidity runway.
- How research and development and infrastructure spending translate into commercial opportunities, including Lumin and the therapeutic discovery pipeline.
- The effect of lease commitments, royalty terms and minimum royalties, and any need for external financing.
- Share-count reconciliation: the balance sheet lists 13,558,650 shares at both October 31, 2022 and April 30, 2022, while the statement of changes in equity lists 13,522,441 shares at April 30, 2022; the filing text does not provide a clear reconciliation.